BCL2 and chronic myelogenous leukemia, BCR-ABL1 positive: Bcl-2 antagonist ABT-199 has been shown to cause on-target cell death in acute myeloid leukemia, and significantly enhances imatinib-induced cell death in chronic myeloid leukemia [32, 33].